Sichenzia Ross Friedman Ference LLP Advises Amarantus on $5M PIPE Investment from Discover Growth Fund

New York, NY – April 29, 2015 – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products in the areas of neurology, psychiatry, ophthalmology and orphan diseases, on a $5 million investment from Discover Growth Fund.

Pursuant to the transaction’s Stock Purchase Agreement, Amarantus issued 1,087 shares of designated Series G Preferred stock at a fixed price of $0.06 per share for gross proceeds of $5,000,000. The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Marcelle Balcombe.

Media Contact:
pr@srf.law
(212)-930-9700

• Author
• Recent Posts

Sichenzia Ross Ference Carmel LLP

SRFC is a full-service law firm with nationally recognized corporate, securities, and litigation practices that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation and regulatory department specializes in defending broker-dealers, registered persons, public and private corporations, and individuals in investigations and enforcement proceedings before the SEC, FINRA, and other regulatory bodies, as well as litigations and arbitrations across all forums in the securities industry, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations.

Latest posts by Sichenzia Ross Ference Carmel LLP (see all)

• Sichenzia Ross Ference Carmel LLP Represents Sharps Technology in $400 Million Private Placement - August 28, 2025
• 美国思成律师事务所代表Dominari Securities、Pacific Century Securities和Revere Securities完成Curanex Pharmaceuticals纳斯达克上市 - August 27, 2025
• Sichenzia Ross Ference Carmel LLP Represents Dominari Securities in $15 Million Initial Public Offering of Curanex Pharmaceuticals - August 27, 2025